Phare Bio

Phare Bio is a social venture dedicated to addressing the urgent global threat of antibiotic resistance through innovative AI and deep learning technologies. The company aims to revolutionize antibiotic discovery and development, ensuring that new antibiotics reach those in greatest need.

PHARE BIO

Phare Bio

https://www.pharebio.org/

info@pharebio.org

What We Do

Generative AI Discovery Engine

Phare Bio is building the world’s first generative AI discovery engine to design and develop novel antibiotics against urgent threats like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.

Digital Health Technologies

Biophysics and Biomedical Modeling

Infectious Diseases

Antibiotic Resistance

Services

Preclinical Development

Diagnostics

Pathology (Biopsies and Blood Tests)

Biologics

Recombinant Proteins

Key People

Akhila Kosaraju

M.D., CEO & President

James J. Collins

Ph.D., Co-founder & Chair of the Scientific Advisory Board

Jonathan M. Stokes

Ph.D., Co-Founder

Leanne Minall

Ph.D., Director of R&D and Scientific Strategy

Joseph Vacca

Ph.D., Medicinal Chemistry

David Pompliano

Ph.D., Anti-Infective Strategy

News & Updates

Phare Bio Awarded Up To $27 Million from ARPA-H to Accelerate AI-Powered Drug Discovery and Develop Critically Needed New Classes of Antibiotics

Phare Bio has received funding to enhance its AI-driven drug discovery efforts, focusing on developing new antibiotics.

ARPA-H Award

Phare Bio is a recent recipient of the ARPA-H Award, aimed at accelerating AI-powered drug discovery.